Technical Analysis for ABUS - Arbutus Biopharma Corporation

Grade Last Price % Change Price Change
grade C 4.38 -0.23% -0.01
ABUS closed down 0.23 percent on Friday, December 14, 2018, on 49 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ABUS trend table...

Date Alert Name Type % Chg
Dec 14 20 DMA Resistance Bearish 0.00%
Dec 14 Bollinger Band Squeeze Range Contraction 0.00%
Dec 13 Fell Below 20 DMA Bearish -0.23%
Dec 13 180 Bearish Setup Bearish Swing Setup -0.23%
Dec 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.23%
Dec 13 Bollinger Band Squeeze Range Contraction -0.23%
Dec 13 Outside Day Range Expansion -0.23%
Dec 12 Crossed Above 20 DMA Bullish -4.78%
Dec 12 Bollinger Band Squeeze Range Contraction -4.78%
Dec 11 Bollinger Band Squeeze Range Contraction -1.35%

Older signals for ABUS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The company's products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Is ABUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.6
52 Week Low 4.01
Average Volume 436,529
200-Day Moving Average 6.9178
50-Day Moving Average 4.8538
20-Day Moving Average 4.566
10-Day Moving Average 4.485
Average True Range 0.3816
ADX 8.87
+DI 14.5224
-DI 14.9905
Chandelier Exit (Long, 3 ATRs ) 4.0252
Chandelier Exit (Short, 3 ATRs ) 5.2848
Upper Bollinger Band 4.8875
Lower Bollinger Band 4.2445
Percent B (%b) 0.21
BandWidth 14.082348
MACD Line -0.1789
MACD Signal Line -0.2128
MACD Histogram 0.034
Fundamentals Value
Market Cap 241.02 Million
Num Shares 55 Million
EPS -5.07
Price-to-Earnings (P/E) Ratio -0.86
Price-to-Sales 164.81
Price-to-Book 1.74
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.77
Resistance 3 (R3) 4.80 4.69 4.71
Resistance 2 (R2) 4.69 4.59 4.68 4.68
Resistance 1 (R1) 4.54 4.53 4.62 4.51 4.66
Pivot Point 4.43 4.43 4.47 4.42 4.43
Support 1 (S1) 4.28 4.33 4.36 4.25 4.10
Support 2 (S2) 4.17 4.27 4.16 4.08
Support 3 (S3) 4.02 4.17 4.06
Support 4 (S4) 3.99